Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) has been granted a patent for its pemetrexed formulations, including the FDA-approved commercial formulation of PEMFEXY®. The patent, which will expire in 2036, has been submitted for listing in the U.S. Food and Drug Administration's Orange Book. This is the second patent to be listed in the Orange Book for PEMFEXY. The company has not received any notice of a Paragraph IV certification for an application referencing PEMFEXY.